“Access to healthcare
Is a basic human right,
And not a privilege reserved for
The rich and for those
Living in developed Countries. ”

In sub-Saharan Africa only a limited number of people can access healthcare. When Pharm Access Africa was incorporated in 2001, per capita spend on health was US$29. At the end of 2007, annual spend on healthcare was estimated to be US$ 20 for Kenya, 3.3 for Madagascar, 19 for Uganda, 12 for Tanzania and 6 Ethiopia compared to the Global figure of US$500.
 
According to UNAIDS figures released in December 2007, of the total 33.2 million people living with HIV/AIDS, close to 22.5 million or over two thirds, live in sub-Saharan Africa.
Pharm Access Africa Limited (PAAL) was set up to increase access to healthcare in general, HIV/AIDS related infections and ART (Anti-Retroviral Therapy) in particular. PAAL provides technical assistance to a number of public and private sector programs and links these initiatives to those of donor organizations to provide care and support.

In one model of this partnership employers underwrite the cost of providing prevention, care and support services with technical support and setting up of AAART laboratories, pharmacies, clinics and other healthcare providers. Family Health International (FHI) finances this project with funding from Presidential Emergency Program for AIDS Relief (PEPFAR).

PAAL seeks to facilitate and strengthen mechanisms for all players to work more collaboratively at country and regional levels, including national AIDS control programs, community groups, civil society, faith based organizations, development partners, donors including the World Bank and The Global Fund for AIDS, tuberculosis, malaria and the private sector.

In another model PAAL is partnering with a venture capitol company, and funding by the development arm of a European country, to provide prevention and treatment facilities for the member companies.

Pharm Access Africa Limited partners with one of the largest non-governmental organizations (NGOs) to bring cost effective contraceptive interventions to some 11 countries in the region. We are working closely with a number of NGOs and national regulatory authorities to audit the manufacturing facility for Good Manufacturing Practice (GMP) and prepare dossier for registration in target countries. These are coupled with pharmaco-vigilance plans which will have the African hub in Nairobi. Latest information and cell phone technology will be employed to answer frequently asked client questions.